Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dingli

Showing results (241-250 of 471) with videos related to

Pageof 48
Sort By:
American Journal of Hematology|May 3, 2012
Trends and outcomes of modern staging of solitary plasmacytoma of boneRahma Warsame, Morie A Gertz, Martha Q Lacy, et al.
Haematologica|August 2, 2016
Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen typeEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
American Journal of Hematology|April 11, 2025
The Impact of Melphalan Conditioning and CD34 <sup>+</sup> Cell Dose and Schedule on Post-Transplant Outcomes in AL AmyloidosisEli Muchtar, Vaishali Sanchorawala, Hamza Hassan, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple MyelomaShaji Kumar, Betsy Knopf, Erik Asmus, et al.
American Journal of Hematology|March 11, 2015
Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin TAngela Dispenzieri, Morie A Gertz, Amy Saenger, et al.
Blood Advances|December 24, 2025
Comprehensive Analysis of Subtype-Specific Outcomes and Management in Castleman Disease: A 20-Year Cohort StudyYoshito Nishimura, Thomas M Habermann, Morie A Gertz, et al.
American Journal of Hematology|October 13, 2016
Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluationYi L Hwa, Qian Shi, Shaji K Kumar, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen typeEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
Blood|June 9, 2025
Eliminating the need for sequential confirmation of response in multiple myelomaJean-Sébastien Claveau, Prashant Kapoor, Moritz Binder, et al.
European Journal of Haematology|February 8, 2014
Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplantRahma Warsame, Soo Mee Bang, Shaji K Kumar, et al.
Pageof 48

Showing results (241-250 of 471) with videos related to

Sort By:
Pageof 48
American Journal of Hematology|May 3, 2012
Trends and outcomes of modern staging of solitary plasmacytoma of boneRahma Warsame, Morie A Gertz, Martha Q Lacy, et al.
Haematologica|August 2, 2016
Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen typeEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
American Journal of Hematology|April 11, 2025
The Impact of Melphalan Conditioning and CD34 <sup>+</sup> Cell Dose and Schedule on Post-Transplant Outcomes in AL AmyloidosisEli Muchtar, Vaishali Sanchorawala, Hamza Hassan, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple MyelomaShaji Kumar, Betsy Knopf, Erik Asmus, et al.
American Journal of Hematology|March 11, 2015
Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin TAngela Dispenzieri, Morie A Gertz, Amy Saenger, et al.
Blood Advances|December 24, 2025
Comprehensive Analysis of Subtype-Specific Outcomes and Management in Castleman Disease: A 20-Year Cohort StudyYoshito Nishimura, Thomas M Habermann, Morie A Gertz, et al.
American Journal of Hematology|October 13, 2016
Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluationYi L Hwa, Qian Shi, Shaji K Kumar, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen typeEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
Blood|June 9, 2025
Eliminating the need for sequential confirmation of response in multiple myelomaJean-Sébastien Claveau, Prashant Kapoor, Moritz Binder, et al.
European Journal of Haematology|February 8, 2014
Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplantRahma Warsame, Soo Mee Bang, Shaji K Kumar, et al.
Pageof 48